Abstracts tagged "leukocytopenia,"

Abstract Number: 1963 • 2019 ACR/ARP Annual Meeting
Combining Clinical and Candidate Gene Data into a Risk Score for Azathioprine-Associated Leukopenia in Routine Clinical Practice
Prathima Anandi ¹, Alyson Dickson ², Qiping Feng ¹, Wei-Qi Wei ², William Dupont ², Dale Plummer ², Ge Liu ¹, Katherine Barker ², Vivian Kawai ², Kelly Birdwell ², Nancy Cox ¹, C. Michael Stein ², Adriana Hung ² and Cecilia Chung³, ¹Vanderbilt University Medical Center, Nashville, ²Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt University, Nashville, TN
Background/Purpose: Azathioprine is a widely-used drug for the treatment of rheumatic diseases, inflammatory bowel disease, and for organ transplantation. However, treatment is often limited by…
Abstract Number: 515 • 2017 ACR/ARHP Annual Meeting
Leukopenia and Tumor Necrosis Factor Alpha Inhibitor Therapy
Wenlu Xiong¹, Rochella A. Ostrowski², William Adams³ and Rodney Tehrani⁴, ¹Rheumatology, Vanderbilt University Medical Center, Nashville, TN, ²Rheumatology, Loyola University Medical Center, Maywood, IL, ³Clinical Research Office, Loyola University Medical Center, Maywood, IL, ⁴Rheumatology & Immunology, Loyola University Medical Center, Maywood, IL
- Background/Purpose: Tumor necrosis factor (TNF) alpha, a key proinflammatory cytokine in rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), has been a major target in…
Abstract Number: 1629 • 2017 ACR/ARHP Annual Meeting
Disease Activity Is an Independent Predictor of Leukopenia in a Large International SLE Cohort
Rangi Kandane-Rathnayake¹, Vera Golder², Worawit Louthrenoo³, Sargunan Sockalingam⁴, Aisha Lateef⁵, Yuan An⁶, Leonid Zamora⁷, Yeong-Jian Wu⁸, Shue-Fen Luo⁹, Madelynn Chan¹⁰, Fiona Goldblatt¹¹, Chak Sing Lau¹², Zhan-Guo Li¹³, Sandra V. Navarra⁷, Mandana Nikpour¹⁴, Eric F Morand¹⁵ and Alberta Y. Hoi², ¹Rheumatology, Monash University, Melbourne, Australia, ²Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ³Division of Rheumatology, Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand, ⁴University of Malaya, Kuala Lumpur, Malaysia, ⁵Medicine, Division of Rheumatology, National University Hospital of Singapore, Singapore, Singapore, ⁶Peking University People's Hospital, Beijing, China, ⁷Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, ⁸Chang Gung University, Taoyuan County, Taiwan, ⁹Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ¹⁰Tan Tock Seng Hospital, Singapore, Singapore, ¹¹Flinders University, Adelaide, Australia, ¹²Univ Dept of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ¹³Peking University International Hospital, Beijing, China, ¹⁴Melbourne University, Melbourne, Australia, ¹⁵Monash University, Melbourne, Australia
Background/Purpose: Leukopenia is commonly seen in SLE, but its predictors are not well understood, as it can be a result of disease activity or bone…
Abstract Number: 2381 • 2017 ACR/ARHP Annual Meeting
Hematologic Abnormalities during the Use of Low Dose Methotrexate for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Kathleen Vanni¹, Zhi Zhang¹, Cassandra Corrigan² and Daniel H. Solomon³, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Methotrexate (MTX) is known to increase the risk of cytopenias, but the prevalence of hematologic abnormalities among patients taking low dose MTX is poorly…
Abstract Number: 2183 • 2012 ACR/ARHP Annual Meeting
Common Features in Lymphoproliferative Complications in the Course of Primary Sjögren’s Syndrome: Results From a Multicenter Cohort of 1170 Patients
Luca Quartuccio¹, Chiara Baldini², Roberta Priori³, Elena Bartoloni Bocci⁴, Francesco Carubbi⁵, Miriam Isola⁶, Marta Maset⁷, Sara Salvin⁷, Nicoletta Luciano², Giovanna Picarelli⁸, Alessia Alunno⁹, Roberto Giacomelli¹⁰, Roberto Gerli¹¹, Guido Valesini¹², Stefano Bombardieri¹³ and Salvatore De Vita¹, ¹Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy, ²University of Pisa, Rheumatology Unit, Pisa, Italy, ³Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, ⁴Rheumatology Unit, Department of Clinical & Experimental Medicine, University of Perugia, Perugia, Italy, ⁵Rheumatology Clinic, University of L'Aquila, L'Aquila, Italy, ⁶Institute of Statistics, University of Udine, Udine, Italy, ⁷Rheumatology Clinic, DSMB, University of Udine, Italy, Udine, Italy, ⁸Rheumatology Unit, Sapienza University of Rome, Rome, Italy, ⁹Clinical and Experimental Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ¹⁰Rheumatology Unit, University of Aquila, L'Aquila, Italy, ¹¹Rheumatology Unit, University of Perugia, Perugia, Italy, ¹²Clinica e Terapia Medica, Sapienza, Universita di Roma, Rome, Italy, ¹³Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: To describe the prevalence of lymphoproliferative complications (defined as B-cell lymphoma or definite conditions predisposing to lymphoma, i.e, cryoglobulinemic vasculitis (CV) and major salivary…